Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

No BS RX vs PauseRX

By GLP-1 ScorecardUpdated

No BS RXFactor scores not reassessed.
Site position #23

Higher score

PauseRXFactor scores not reassessed.
Site position #162

Lower score

Score comparison

No BS RX has the higher recorded score — 82.8/100 to 68.5/100.

No BS RX grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. No BS RX publishes separate prices for standard compounded, low-dose and brand-name programs.

Before you choose

Before comparing the headline prices, the No BS RX review and the PauseRX review set out the plan length, renewal date and extra fees behind each semaglutide figure in the table below, and the semaglutide cost page compares published rates across the field. A lower starting price can still mean a larger bill once a longer commitment or a separate membership is added.

If neither one fits, No BS RX vs PCOS Sisters and Options Medical Weight Loss vs PauseRX compare each of them with another graded program, and the list of alternatives to No BS RX ranks the programs closest to No BS RX on price, features and score. Those pages, like every entry in the review directory, use the same six graded factors, so the scores carry across.

Of the sellers that pay us a commission, the Belle Health review covers one graded close to these two, at 73.8/100. That relationship never changes a grade, and the review lists what we could not verify.

We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.

Factor by factor

These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.

Cost valueNo BS RX +26
92
66
Dose & formulationNo BS RX +5
90
85
Clinical oversightPauseRX +11
72
83
Labs & monitoringNo BS RX +16
68
52
FulfillmentNo BS RX +33
94
61
Contract termsNo BS RX +33
74
41
No BS RX · top barPauseRX · bottom bar

The numbers

Swipe or scroll to compare both providers.

MetricNo BS RXPauseRX
WeighScore82.8/10068.5/100
GradeB−C
Site position#23#162
Semaglutide$149/mo advertised for standard compounded injection; low-dose priced separatelyCompounded GLP-1 from $199; confirm selected supply and charge
Tirzepatide$225/mo advertised for standard compounded injection; low-dose priced separatelyCompounded GLP-1/GIP from $249; confirm selected supply and charge
CoverageConfirm program availability for your stateConfirm availability for the selected product and state
Brand-name accessYesYes
Oral / sublingualYesYes
No BS RX

Site position #23 · B−

Factor scores not reassessed.

Strengths

  • Displays monthly and prepaid amounts by program
  • Advertises consultation, medication, shipping and messaging in the compounded plans
  • Lists branded Ozempic and Zepbound separately

What to consider

  • The $115 headline applies to low-dose programs
  • Plans renew automatically at the then-current rate
  • Cancellation generally stops future billing without refunding the current period
PauseRX

Site position #162 · C

Factor scores not reassessed.

Strengths

  • Publishes starting prices for its two compounded programs
  • Lists brand-name options separately
  • Publishes a prescription final-sale policy

What to consider

  • Starting prices do not establish the full debit or refill charge
  • The returns policy makes charged orders final after carrier handoff

Featured provider

CoreAge Rx

CoreAge Rx scores 89.5/100 (B+). Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.

Commercial relationships affect this placement. The score comparison above is separate.

Prices and terms can change; confirm them with the provider. Our factor scores may reflect earlier assessments; see our methodology. Not medical advice; see our disclosure.

← Back to the scorecard